Oxford says the vaccine has a good immune response with the two-dose regimen

LONDON: Oxford’s Covid-19 vaccine candidate has a better immune response when a full two-dose regimen is used rather than a full-dose followed by a half-dose booster, the university said Thursday.
The vaccine candidate, which has been licensed to AstraZeneca, has published the results of late-stage interim studies showing greater efficacy when a half dose is followed by a full dose, compared to a full two-dose regimen, although it is necessary to do more work to affirm the result.
Details of the Phase I / II clinical trials released Thursday did not refer to the half-dose / full-dose regimen, which Oxford said was “unplanned” but approved by regulators.
The university said it explored two dosing regimens in the early trial stages, a full-dose / full-dose regimen and a full-dose / half-dose regimen, studied as a possible ‘dose reduction’ strategy.
“Booster doses of the vaccine have both been shown to induce stronger antibody responses than a single dose, the standard dose / standard dose that induces the best response,” the university said in a statement.
The vaccine “stimulates extensive antibody and T-cell functions,” he said after publishing additional data from Phase I / II clinical trials.